Original release date: June 11, 2024
Course Description
USCAP Myeloproliferative and Myelodysplastic Neoplasms: The Past, Present, and Future 2024 In the era of the rapid development of new diagnostic modalities and novel targeted treatment options, a comprehensive diagnostic approach to myelodysplastic and myeloproliferative neoplasms becomes ever more critical. However, the rapidly evolving scientific and technological discoveries that have been continuously incorporated into the classification of myelodysplastic and/or myeloproliferative neoplasms significantly increase already complex hematopathology practice. (Hemato)pathologists are currently facing the following challenges:
- How to stay abreast of this avalanche of data?
- How to incorporate the data into my day-to-day practice?
- What testing should I order to correctly classify myelodysplastic and myeloproliferative neoplasms?
- How should my diagnosis be worded in the face of two new classifications of hematologic neoplasms (5th edition WHO and 2022 International Consensus Classifications).
